NATO Makes First Dutch Investment in Bacterial Detection Technology
Amsterdam, Thursday, 2 April 2026.
The NATO Innovation Fund invested $16 million in Amsterdam-based Inbiome, marking NATO’s first investment in a Dutch startup. Inbiome’s revolutionary diagnostic platform identifies bacterial infections in just five hours compared to traditional methods requiring three to four days. The technology detects 50% more bacterial pathogens and has already received European certification, with deployment across 20+ hospitals. NATO’s investment reflects urgent military needs, as 80% of battlefield wounds in Ukraine involve antibiotic-resistant bacteria. This breakthrough could transform both civilian healthcare and military medicine by enabling faster, targeted treatment decisions.
Revolutionary Healthcare Technology Transforms Infection Diagnostics
This development represents a significant advancement in healthcare technology, specifically medical diagnostics for bacterial infections [GPT]. Inbiome’s Molecular Culture® technology combines machine learning with innovative chemistry to profile the bacterial microbiome, detecting all bacterial DNA and converting it into unique barcodes through an advanced AI platform [1]. This approach enables identification of all bacteria present within hours, fundamentally transforming clinical microbiology which has relied on culture-based methods for decades [2]. The platform received IVDR certification for the European Union in April 2025, allowing deployment across European hospital laboratories [2][3]. Currently, the technology covers seven types of infections in Europe, including joint infections and meningitis, with deployment in over twenty major hospitals including Amsterdam UMC [6].
Substantial Financial Backing and Strategic Partnerships
The Series A financing round, announced on April 1, 2026, raised $16 million with the NATO Innovation Fund serving as co-lead investor alongside Slingshot Ventures and Michiel Boehmer [2][3]. This investment represents NATO’s first funding commitment to a Dutch startup, highlighting the strategic importance of rapid diagnostic capabilities [1][3]. The NATO Innovation Fund, established under the NATO 2030 initiative, manages over €1 billion in assets backed by 24 NATO allies, focusing on deeptech startups addressing defense, security, and resilience challenges [1]. Notably, the United States does not contribute to this fund [1]. Former Unilabs CEO Michiel Boehmer will serve as an advisor to Inbiome following the investment [2].
Company Leadership and Technological Innovation
Inbiome was founded in 2019 by Dutch brothers Dries Budding, who serves as CEO, and Jord Budding, the company’s COO [3][6]. The founding team deliberately chose a contrarian approach to bacterial detection technology. As CEO Dries Budding explained, while others pursued complex whole genome sequencing technologies, Inbiome went “in a completely opposite direction” despite initial skepticism, ultimately proving their simplified approach was correct [3]. COO Jord Budding articulated the company’s ambitious vision: “Our ambition is clear: same-day diagnostics for all infectious diseases” [2]. The platform utilizes existing hospital technology infrastructure, making implementation more seamless for healthcare facilities [3].
Critical Military Applications and Global Health Impact
The investment addresses urgent military medical needs, particularly relevant given current global conflicts. According to Dries Budding, antimicrobial resistance has reached critical levels on battlefields, with 80% of wounds in Ukraine affected by multi-drug-resistant bacteria, causing deaths from previously treatable bacterial infections [3][6]. NIF Partner Erin Hallock emphasized the technology’s strategic importance: “This supports NATO’s mandate to strengthen both civilian resilience and military medicine readiness for antimicrobial resistant pandemics and bio threats” [3]. Amalia Kontesi, chief communications and marketing officer of NIF, noted that NATO recognizes significant opportunities to improve infection diagnostics in conflict zones, citing Ukraine as a primary example [1][6]. The technology enables rapid identification of antibiotic-resistant pathogens, allowing for targeted treatment decisions rather than broad-spectrum antibiotic use that can worsen resistance patterns [5].
Future Market Expansion and Development Plans
The funding will support Inbiome’s expansion strategy across Europe and accelerate U.S. market entry, where the company has received FDA Breakthrough Device Designation and is pursuing full approval [2][3]. Production scaling and commercial rollout across Europe represent immediate priorities, with certification for blood samples expected soon and urine testing to follow later in 2026 [2]. Future development plans include adding fungal diagnostics capabilities and creating an add-on application to identify specific genes contributing to antibiotic resistance [3]. The company is also developing a testing setup within a shipping container capable of processing 500 tests daily, designed for deployment in challenging environments including conflict zones [3]. Ana Bernardo-Gancedo, Senior Associate at NATO Innovation Fund, expressed enthusiasm about the potential impact: “We are excited about the potential of Inbiome – our first investment in the Netherlands – to deliver targeted and faster diagnostics to the people who need them the most” [2].